PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs: An Interclone Evaluation by Differently Trained Pathologists.

Munari, Enrico

PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs: An Interclone Evaluation by Differently Trained Pathologists. [electronic resource] - The American journal of surgical pathology 10 2018 - 1384-1389 p. digital

Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

1532-0979

10.1097/PAS.0000000000001105 doi


Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized--therapeutic use
Antineoplastic Agents, Immunological--therapeutic use
B7-H1 Antigen--analysis
Biomarkers, Tumor--analysis
Carcinoma, Non-Small-Cell Lung--chemistry
Chemotherapy, Adjuvant
Clinical Decision-Making
Female
Humans
Immunohistochemistry--methods
Lung Neoplasms--chemistry
Male
Middle Aged
Observer Variation
Pathologists--education
Patient Selection
Predictive Value of Tests
Reagent Kits, Diagnostic
Reproducibility of Results
Tissue Array Analysis